Recommendation of the President – Ultomiris (ravulizumab)
On 6 August 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 85/2024 on the evaluation of the drug Ultomiris (ravulizumab) within the framework of the drug program “Treatment of patients with generalized form of myasthenia gravis (G70.0)”